BALTIMORE – miDIAGNOSTICS will collaborate with emocha Mobile Health to develop a mobile diagnostics lab and analytic platform.
“Adding emocha Mobile Health as a collaborator, we have chosen a top expert in the field of mobile health, connectivity and data management,” said Peter Peumans, vice president and program director of life science technology at imec, in a statement.
imec is the nanoelectrics research and development center collaborating with miDIAGNOSTICS and Johns Hopkins to develop diagnostic tests integrated in silicon chips that will act as miniaturized labs, able to detect cells, proteins, nucleic acids or small molecules from a tiny volume of body fluid. The emocha platform will connect the tests and their results to the laptops, tablets or smartphones of patients and caregivers through a mobile app, creating a mobile health solution for diagnostics at the point-of-need.
The system’s dashboard will offer a customizable view of test results, allowing test and data analysis.
“The cloud infrastructure is the central hub transforming future miDIAGNOSTICS products into impactful mobile health solutions that links patient results to providers and health systems electronic records,” said Hilja Ibert, CEO of miDIAGNOSTICS.
“Our mission is to help transform public health through mobile technology,” said Sebastian Seiguer, co-founder and CEO of emocha, in a statement.
Seiguer said the company hopes to be able to add this point-of-need testing to its mobile health interventions for a variety of use cases, including Hepatitis C medication adherence.
“Care has shifted rapidly to the outpatient setting, and our integrated solutions will enable providers to strongly support patients wherever they may be,” Seiguer said.